Rising to the technological challenge: possibilities for integration of biotechnology in the Indian pharmaceutical industry Online publication date: Sun, 13-Jul-2003
by Shyama V. Ramani, M.S. Venkataramani
International Journal of Biotechnology (IJBT), Vol. 3, No. 1/2, 2001
Abstract: Presently, the Indian pharmaceutical industry ranks 12th in the world and its market is conservatively estimated to be $2.5 billion. Tracing the evolution of this industry, the paper first shows that Indian firms over the years had invested in gaining knowledge of the chemical technology of creating bulk drugs, and the top tier firms had greatly ''learnt by doing'', improving upon the process technology and bringing down their prices without investing in ''formal R&D centers''. These firms were then confronted with biotechnology, a set of techniques that was new and more complex to integrate. In this context the paper examines the variety of ways in which the Indian firms are strategically positioning themselves for the integration of biotechnology as dictated by their market objectives.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com